0,1,2,3,4,5,6,7
Table 6.3.10:  Treatment-related toxicity and BCR-free survival in selected SABR studies,,,,,,,
Study,Study design,n and   RT-type,Median   FU (mo),Fractionation  (SD/TD),ADT,Treatment   toxicity,BCR-free   survival
"Bergamin,   et al. 2020   [1096]",single-centre   prospective,25   LINAC  based,25,SD 6-6.2  TD 36-38 Gy,0/25,2 yr. late   G1 GI 8%   G2 GU 4%,2 yr. 80%
"Fuller, et al.   2020 [1095]",single-centre   retrospective,50  Cyber Knife,44,SD 6.8 Gy  TD 34 Gy,7/50,5 yr: 8% late   G3+ GU,5 yr. 60%
"Pasquier,   et al. 2020   [1094]",multi-centre   retrospective,100   Cyber Knife,30,SD 6 Gy  TD 36 Gy,34/100  median   12 mo.,3 yr. grade 2+   GU 20.8%  GI 1%,3 yr. 55%
